Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Roger Hatharasinghe

Internal Medicine Statesville, NC Medical Doctor

NPI 1477545986 CMS profile 67000

138 Sherlock Dr, Statesville, NC 28625

Open in the dashboard

General payments

$4,851

348 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$164,301 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Roger Hatharasinghe of Statesville, NC is reported in the CMS Open Payments database as having received $4,851 across 348 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $164,301 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $902 54
2024 General $679 40
2023 General $549 39
2022 General $526 34
2021 General $352 34
2020 General $270 18
2019 General $1,573 129

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Roger Hatharasinghe
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Roger Hatharasinghe were reported at $902. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Roger Hatharasinghe Internal Medicine median Middle half National median
2019 $1,573 $159 $48–$570 $163
2020 $270 $119 $33–$402 $114
2021 $352 $135 $37–$521 $132
2022 $526 $141 $42–$496 $149
2023 $549 $149 $45–$519 $160
2024 $679 $154 $47–$537 $164
2025 $902 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,856 152 payments
  2. Pfizer Inc. $563 42 payments
  3. Amgen Inc. $426 27 payments
  4. AbbVie, Inc. $263 15 payments
  5. Merck Sharp & Dohme Corporation $155 12 payments
  6. Sanofi-Aventis U.S. LLC $144 12 payments
  7. Dexcom, Inc. $133 5 payments
  8. AstraZeneca Pharmaceuticals LP $121 7 payments
  9. Supernus Pharmaceuticals, Inc. $111 6 payments
  10. Astellas Pharma US Inc $79 6 payments
  11. Other $1,000 64 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,851 348 payments
Products named General payments · program years 2019–2025
  1. Ozempic $879 78 payments
  2. RYBELSUS $739 62 payments
  3. Wegovy $452 36 payments
  4. Saxenda $389 26 payments
  5. ELIQUIS $336 23 payments
  6. Repatha $225 15 payments
  7. NURTEC ODT $208 11 payments
  8. EVENITY $186 11 payments
  9. Prolia $160 10 payments
  10. AIMOVIG $155 11 payments
  11. Other $3,381 239 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 190 drugs

Part D claims

15,472

Median for Internal Medicine: 777

Drug cost

$1,116,132

Median for Internal Medicine: $73,373

Branded share of claims

22.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 208 $194,761
Ozempic Semaglutide Brand 133 $182,417
Eliquis Apixaban Brand 135 $108,261
Mounjaro Tirzepatide Brand 84 $88,869
Prolia Denosumab Brand 29 $51,129
Synjardy Xr Empagliflozin/Metformin Hcl Brand 43 $39,026
Janumet Sitagliptin Phos/Metformin Hcl Brand 26 $30,147
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 79 $24,647
Xarelto Rivaroxaban Brand 24 $23,085
Shingrix Varicella-Zoster Ge/As01b/Pf Brand 103 $22,987

The 10 drugs with the highest cost, of 190 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 155 billing codes

Paid by Medicare

$178,401

Of which drugs: $27,227

Medicare patients

514

Average age 74

Services billed

8,122

298 women, 216 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Diabetes 31%
Ischemic heart disease 26%
Chronic kidney disease 23%
COPD 23%
Cancer 18%
Depression 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 73 73 $20,883
Vaccine for influenza for injection into muscle 90662 Office 74 74 $5,966
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 22 2,210 $202
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 25 97 $73

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $115
$115 — —
RYBELSUS
  • Novo Nordisk Inc $49
$49 — —
Ozempic
  • Novo Nordisk Inc $49
$49 133 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $29
$29 — —
VYEPTI
  • Lundbeck LLC $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

348 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record